AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26356708
Drug: Dalteparin 5000
RxNorm normalized name: dalteparin 5000 intl units/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin 5000 IU once daily
Trial: 26356708
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin (UFH) 5000 IU twice daily
Trial: 17600649
Drug: Treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm guess
Trial: 16636358
Drug: Sucrose (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (2 mL)
Trial: 12748500
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol replacement
Trial: 12940591
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol replacement
Trial: 10978944
Drug: Lactase tablets
RxNorm normalized name: Lactase
DrugBank: Tilactase (DB13761)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactase tablets
Trial: 8595970
Drug: timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: timolol 0.5% twice a day (b.i.d.)
Trial: 7034473
Drug: Metoprolol 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 15 mg IV followed by a total daily dose of 200 mg/day
Trial: 28673363
Drug: RYR-olive extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RYR-olive extract (10.82 mg of monacolins and 9.32 mg of hydroxytyrosol per capsule)
Trial: 23298376
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg/day for 14 days
Trial: 19302635
Drug: Esmolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (1 mg.kg(‐1) bolus followed by 250 microg.kg(‐1)min(‐1) infusion)
Trial: 17515571
Drug: Radiotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy only or nonalkylating chemotherapy (ABVD, EBVP)
Trial: 17515571
Drug: Chemotherapy containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy containing alkylating agents (MOPP, ABV, BEACOPP)
Trial: 17515571
Drug: Nonalkylating chemotherapy
RxNorm normalized name: petroleum alkylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonalkylating chemotherapy
Trial: 17515571
Drug: Alkylating chemotherapy
RxNorm normalized name: petroleum alkylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkylating chemotherapy
Trial: 17515571
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of alkylating chemotherapy
Trial: 11472042
Drug: Invasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive treatment (open surgical or endovascular procedures)
Trial: 9492829
Drug: 5'-deoxy-5-fluorouridine (5'-DFUR)
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'-deoxy-5-fluorouridine (5'-DFUR) administration at a dose of 1,200 mg/body for 7 days
Trial: 8049831
Drug: Active patch
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active patch delivering 11 mg of nicotine over 24 hours
Trial: 25500202
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g inulin-propionate ester
Trial: 25500202
Drug: 10 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/day inulin-propionate ester supplementation
Trial: 23363981
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no probucol treatment)
Trial: 18436353
Drug: Intradermal immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal immunization (0.1 ml of trivalent influenza vaccine)
Trial: 18436353
Drug: Intradermal immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal immunization
Trial: 18436353
Drug: Subcutaneous immunization
RxNorm normalized name: immune globulin subcutaneous (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunization (0.1 ml of trivalent influenza vaccine)
Trial: 18436353
Drug: Subcutaneous immunization
RxNorm normalized name: immune globulin subcutaneous (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunization
Trial: 14510756
Drug: Ionic low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ionic low osmolar agent
Trial: 14510756
Drug: Non-ionic, iso-osmotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ionic, iso-osmotic agent
Trial: 14510756
Drug: Non-ionic, low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ionic, low osmolar agent
Trial: 3083851
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (350 mg intravenously)
Trial: 3083851
Drug: Sodium salicylate
RxNorm normalized name: Sodium Salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium salicylate (1200 mg daily for 3 days)
Trial: 3083851
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (60.7 mg kg‐1 for 8 days)
Trial: 3083851
Drug: Sodium salicylate
RxNorm normalized name: Sodium Salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium salicylate (52.6 mg kg‐1 for 8 days)
Trial: 29898752
Drug: Trastuzumab and
RxNorm normalized name: pertuzumab and trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab and chemotherapy (Arms B and C)
Trial: 29898752
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (Arm A)
Trial: 28115966
Drug: Walnut oil
RxNorm normalized name: Walnut oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut oil (15 g/day for three months)
Trial: 21265206
Drug: Hook needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hook needle knife treatment
Trial: 17935553
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (1000 mg/day)
Trial: 15736119
Drug: Low rate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low rate of insulin infusion (1.5 mU insulin/kg per minute)
Trial: 15736119
Drug: High rate
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High rate of insulin infusion (15 mU insulin/kg per minute)
Trial: 12137603
Drug: ACEI group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI group (benazepril 10 mg/d)
Trial: 2550045
Drug: Perindopril (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (8 mg oral)
Trial: 2550045
Drug: Perindoprilat (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindoprilat (2 mg intravenously)
Trial: 2550045
Drug: Perindopril (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (8 mg oral) and Perindoprilat (2 mg intravenously)
Trial: 4608503
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (SK) therapy
Trial: 30985244
Drug: PPIC 2.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPIC 2.1 survey administered to beneficiaries
Trial: 29717841
Drug: Triple acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple acupuncture at the Qugu acupoint (twice a week for 4 weeks)
Trial: 29717841
Drug: Levofloxacin Mesylate
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin Mesylate Tablets (0.5 g, tid) + Terazosin Hydrochloride Capsules (2 mg qd) for 4 weeks
Trial: 18413983
Drug: Venous thromboembolism
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venous thromboembolism prophylaxis (mechanical, pharmacological, or a combination of both)
Trial: 1612952
Drug: Hypothalamic‐pituitary radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothalamic‐pituitary radiation therapy
Trial: 6145533
Drug: Prenalterol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenalterol (1 mg/hr)
Trial: 6145533
Drug: Prenalterol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenalterol (2 mg/hr)
Trial: 6145533
Drug: Salbutamol (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (low dose)
Trial: 23147138
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of RIX4414 vaccine (n = 328)
Trial: 21056809
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 1 μg/mL
Trial: 21056809
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 2 μg/mL
Trial: 21056809
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 3 μg/mL
Trial: 21056809
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 4 μg/mL
Trial: 21056809
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 5 μg/mL
Trial: 21056809
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 6 μg/mL
Trial: 9882082
Drug: Dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen trometamol 50 mg
Trial: 14570662
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl infusion (30 microg/h)
Trial: 14570662
Drug: IV fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV fentanyl infusion (30 microg/h)
Trial: 11115439
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution perfusion
Trial: 9175684
Drug: Plasma interleukin-1
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma interleukin-1 receptor antagonist (IL-1ra) levels in pre-eclampsia group
Trial: 9175684
Drug: Plasma interleukin-1
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma interleukin-1 receptor antagonist (IL-1ra) levels in uncomplicated pregnancy group
Trial: 1564652
Drug: Conventional monofocal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional monofocal implant
Trial: 3890786
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy alone (32 patients)
Trial: 3890786
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy plus BCG vaccine (24 patients)
Trial: 3890786
Drug: Ten-day chemotherapy
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten-day chemotherapy (vincristine sulfate, cytarabine, prednisone)
Trial: 3890786
Drug: Five-day chemotherapy
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-day chemotherapy (cytarabine)
Trial: 28710229
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days of antibiotic therapy
Trial: 30831300
Drug: Diagnostic transforaminal
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic transforaminal epidural injection (DTEI)
Trial: 24368436
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g LNS/d
Trial: 24368436
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g LNS/d
Trial: 24368436
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g LNS/d
Trial: 24481578
Drug: Subcutaneously implanted
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously implanted epidural ports (SIEP) with morphine administration (starting with 2 mg, maximum 4 mg per day)
Trial: 24481578
Drug: Subcutaneously implanted
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously implanted epidural ports (SIEP) with morphine administration
Trial: 22627883
Drug: FEIBA (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEIBA (lower doses)
Trial: 17056272
Drug: Cuban recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuban recombinant hepatitis B vaccine (Heberbiovac HB), 20 microg HBsAg/mL, administered in three doses at month 0, 1, and 2.
Trial: 17134634
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy in white patients
Trial: 17134634
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy in black patients
Trial: 12565987
Drug: 5-FU 60
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 60 mg/kg as a continuous infusion over 48 h, with methotrexate 40 mg/m(2) administered just before 5-FU (control regimen)
Trial: 12565987
Drug: PALA 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PALA 250 mg/m(2) as a 15 min infusion administered 24 h before 5-FU and methotrexate
Trial: 1328817
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (15 g/d for 4 weeks)
Trial: 1328817
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (15 g/d for 4 weeks)
Trial: 4062571
Drug: Cholestyramine 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 8 gm twice daily, p.m. dose at different times
Trial: 4062571
Drug: Cholestyramine 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 8 gm twice daily, p.m. dose 30 minutes before evening meal
Trial: 4062571
Drug: Cholestyramine 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 8 gm twice daily, p.m. dose mid-afternoon
Trial: 4062571
Drug: Cholestyramine 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 8 gm twice daily, all treatment periods
Trial: 23588485
Drug: Self-administered PNF
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered PNF hamstring stretching 2 × 40 seconds on each leg for 6 weeks
Trial: 18083322
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy for pregnant substance users (MET‐PS)
Trial: 10703890
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (verapamil 180 mg plus trandolapril 2 mg)
Trial: 10703890
Drug: Monotherapy (dose-titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (dose-titration or switching to a different drug class)
Trial: 8732126
Drug: Shuxuening tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuxuening tablet No. 1 (crude extract)
Trial: 8732126
Drug: Shuxuening tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuxuening tablet No. 2 (pure extract)
Trial: 8732126
Drug: Shuxuening tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuxuening tablet No. 1 and No. 2
Trial: 1748495
Drug: Misoprostol 200
RxNorm normalized name: MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 200 micrograms twice daily for 4 weeks
Trial: 1748495
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets twice daily for 4 weeks
Trial: 7140487
Drug: Chenodeoxycholic (chenic)
RxNorm normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic (chenic) acid, 15 mg/kg/day, administered in three divided doses at mealtimes with an unrestricted diet (Group A)
Trial: 7140487
Drug: Bedtime administration
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime administration of chenodeoxycholic (chenic) acid, 15 mg/kg/day, with a low cholesterol diet (Group B)
Trial: 30228368
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic infiltration with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine
Trial: 28072552
Drug: Dextenza (sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextenza (sustained-release dexamethasone intracanalicular insert)
Trial: 16813177
Drug: Needle-picking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-picking therapy at bilateral Shengzhi points, Dicong Shenjing points and L2 Shenjing points
Trial: 16813177
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Wuzi Yanzong Pills
Trial: 12635531
Drug: Remifentanil-propofol (remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil-propofol (remifentanil 0.4 microgram/kg and propofol 1 mg/kg)
Trial: 12635531
Drug: Alfentanil-propofol (alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil-propofol (alfentanil 20 micrograms/kg and propofol 1 mg/kg)
Trial: 10720025
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy (starting dose, 10 microg/kg x day, final dose 4 microg/kg x day)
Trial: 25233155
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy
Trial: 30014331
Drug: Saline instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline instillation (SI) 20-mL/kg of body weight
Trial: 25635958
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 0.2 mL of monosodium glutamate (1.0 M) into the masseter muscle
Trial: 25635958
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 0.2 mL of monosodium glutamate (1.0 M) into the TMJ
Trial: 18368945
Drug: Nanopril (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanopril (test formulation)
Trial: 9552084
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone injections (n=22)
Trial: 7848350
Drug: Test patch
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test patch (Deponit 5)
Trial: 7848349
Drug: Reference patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference patch
Trial: 3153709
Drug: oxaprotiline (75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaprotiline (75, 150, 225 mg/day for 4 weeks)
Trial: 3153709
Drug: doxepin (75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxepin (75, 150, 225 mg/day for 4 weeks)
Trial: 23238616
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (α-LA) 600 mg intravenous injection daily for 5 days
Trial: 18849890
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (general)
Trial: 17081897
Drug: 5 IU/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 IU/mL low-molecular-weight heparin (LMWH) in the infusion fluid
Trial: 10848883
Drug: DHEA 50
RxNorm normalized name: Natrol Mood & Stress DHEA 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 50 mg
Trial: 10848883
Drug: DHEA 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 200 mg
Trial: 30004919
Drug: More frequent
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More frequent imaging (monthly)
Trial: 19996069
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with a systolic blood pressure target of <130 mm Hg, using valsartan (160 or 320 mg) plus amlodipine (5 or 10 mg)
Trial: 19996069
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with a systolic blood pressure target of <140 mm Hg, using valsartan (160 or 320 mg) plus amlodipine (5 or 10 mg)